Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 3/2016

01-06-2016 | Original Article

Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit

Authors: Akira Munakata, Masato Naraoka, Takeshi Katagai, Norihito Shimamura, Hiroki Ohkuma

Published in: Translational Stroke Research | Issue 3/2016

Login to get access

Abstract

Endothelial dysfunctions that include decreased nitric oxide (NO) bioactivity and increased endothelin-1 (ET-1) bioactivity have been considered to be involved in the pathogenesis of cerebral vasospasm (CVS) after aneurysmal subarachnoid hemorrhage (SAH). Recent cardiovascular studies have revealed that cyclooxygenase-2 (COX-2) is involved in a disturbance in cross-talk between NO and ET-1. COX-2 expression was detected in the endothelial cells of a spastic artery after experimental SAH; however, the pathophysiological significance of COX-2 in relation to CVS remains unclear. The aim of this study was to investigate the role of COX-2 in relation to NO and ET-1 in the pathogenesis of CVS by using the COX-2 selective inhibitor, celecoxib. In the SAH group, SAH was simulated using the double-hemorrhage rabbit model. In the celecoxib group, SAH was simulated and celecoxib was administered. The basilar artery was extracted on day 5 and examined. The cross-section area of the basilar artery in the celecoxib group was significantly larger than in the SAH group. An increased expression of COX-2, ET-1, and ETA receptor (ETAR), and a decreased expression of endothelial NO synthase (eNOS) were seen in the SAH group. In the celecoxib group compared to the SAH group, expression of COX-2, ET-1, and ETAR were statistically significantly decreased, and eNOS expression was significantly increased. COX-2 might be involved in the pathogenesis of CVS due to up-regulation of ET-1 and ETAR and down-regulation of eNOS, and celecoxib may potentially serve as an agent in the prevention of CVS after SAH.
Literature
1.
Tso MK, Macdonald RL. Subarachnoid hemorrhage: a review of experimental studies on the microcirculation and the neurovascular unit. Transl Stroke Res. 2014;5:174–89.CrossRefPubMed
2.
Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res. 2013;4:432–46.CrossRefPubMedPubMedCentral
3.
4.
Dreier JP. The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease. Nat Med. 2011;17:439–47.CrossRefPubMed
5.
6.
7.
Etminan N. Aneurysmal subarachnoid hemorrhage—status quo and perspective. Transl Stroke Res. 2015;6:167–70.CrossRefPubMed
8.
Weidauer S, Lanfermann H, Raabe A, Zanella F, Seifert V, Beck J. Impairment of cerebral perfusion and infarct patterns attributable to vasospasm after aneurysmal subarachnoid hemorrhage: a prospective MRI and DSA study. Stroke. 2007;38:1831–6.CrossRefPubMed
9.
Crowley RW, Medel R, Dumont AS, Ilodigwe D, Kassell NF, Mayer SA, et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke. 2011;42:919–23.CrossRefPubMed
10.
Brathwaite S, Macdonald RL. Current management of delayed cerebral ischemia: update from results of recent clinical trials. Transl Stroke Res. 2014;5:207–26.CrossRefPubMed
11.
Maeda Y, Tani E, Miyamoto T. Prostaglandin metabolism in experimental cerebral vasospasm. J Neurosurg. 1981;55:779–85.CrossRefPubMed
12.
Sasaki T, Murota SI, Wakai S, Asano T, Sano K. Evaluation of prostaglandin biosynthetic activity in canine basilar artery following subarachnoid injection of blood. J Neurosurg. 1981;55:771–8.CrossRefPubMed
13.
Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci U S A. 1991;88:2692–6.CrossRefPubMedPubMedCentral
14.
Osuka K, Suzuki Y, Watanabe Y, Takayasu M, Yoshida J. Inducible cyclooxygenase expression in canine basilar artery after experimental subarachnoid hemorrhage. Stroke. 1998;29:1219–22.CrossRefPubMed
15.
Tran Dinh YR, Jomaa A, Callebert J, Reynier-Rebuffel AM, Tedgui A, Savarit A, et al. Overexpression of cyclooxygenase-2 in rabbit basilar artery endothelial cells after subarachnoid hemorrhage. Neurosurgery. 2001;48:626–33.CrossRefPubMed
16.
Desjardins F, Aubin MC, Carrier M, Perrault LP. Decrease of endothelin recepter subtype ETB and release of COX-derived products contribute to endothelial dysfunction of porcine epicardial coronary arteries in left ventricular hypertrophy. J Cardiovasc Pharmacol. 2005;45:499–508.CrossRefPubMed
17.
Zhou Y, Mitra S, Varadharaj S, Parinandi N, Zweier JL, Flavahan NA. Increased expression of cyclooxygenase-2 mediates enhanced contraction to endothelin ETA receptor stimulation in endothelial nitric oxide synthase knockout mice. Circ Res. 2006;98:1439–45.CrossRefPubMed
18.
Hink U, Munzel T. COX-2, another important player in the nitric oxide-endothelin cross-talk : good news for COX-2 inhibitor? Circ Res. 2006;98:1344–6.CrossRefPubMed
19.
Pluta RM. Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Neurol Res. 2006;28:730–7.CrossRefPubMed
20.
Kikkawa Y, Kurogi R, Sasaki T. The single and double blood injection rabbit subarachnoid hemorrhage model. Transl Stroke Res. 2015;6:88–97.CrossRefPubMed
21.
Mori K. Double cisterna magna blood injection model of experimental subarachnoid hemorrhage in dogs. Transl Stroke Res. 2014;5:647–52.CrossRefPubMed
22.
Wahn H, Wolf J, Kram F, Frantz S, Wagner JA. The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. Am J Physiol Heart Circ Physiol. 2005;289:2491–6.CrossRef
23.
Boiti C, Guelfi G, Brecchia G, Dall’Aglio C, Ceccarelli P, Maranesi M, et al. Role of the endothelin-1 system in the luteolytic process of pseudopregnant rabbits. Endocrinology. 2005;146:1293–300.CrossRefPubMed
24.
Boiti C, Zampini D, Guelfi G, Paolocci F, Zerani M, Gobbetti A. Expression patterns of endothelial and inducible nitric oxide synthase isoforms in corpora lutea of pseudopregnant rabbits at different luteal stages. J Endocrinol. 2002;173:285–96.CrossRefPubMed
25.
Chen M, Kakutani M, Minami M, Kataoka H, Kume N, Narumiya S, et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol. 2000;20:1107–15.CrossRefPubMed
26.
Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Lab Investig. 2012;92:1115–28.CrossRefPubMed
27.
Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in apoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443–52.CrossRefPubMed
28.
Jacobs S, Laury-Kleintop L, Lanza-Jacoby S. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E−/− mice. J Surg Res. 2008;146:135–42.CrossRef
29.
Hino A, Tokuyama Y, Weir B, Takeda J, Yano H, Bell GI, et al. Changes in endothelial nitric oxide synthase mRNA during vasospasm after subarachnoid hemorrhage in monkeys. Neurosurgery. 1996;39:562–7.PubMed
30.
Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS. Role of endothelial no synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke. 2005;36:2731–7.CrossRefPubMed
31.
Kasuya H, Weir BK, Nakane M, Pollock JS, Johns L, Marton LS, et al. Nitric oxide synthase and guanylate cyclase levels in canine basilar arteries after subarachnoid hemorrhage. J Neurosurg. 1995;82:250–5.CrossRefPubMed
32.
Sabri M, Ai J, Knight B, Tariq A, Jeon H, Shang X, et al. Uncoupling of endothelial nitric oxide synthase after experimental subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2010;31:190–9.CrossRefPubMedPubMedCentral
33.
Neuschmelting V, Marbacher S, Fathi AR, Jakob SM, Fandino J. Elevated level of endothelin-1 in cerebrospinal fluid and lack of nitric oxide in basilar arterial plasma associated with cerebral vasospasm after subarachnoid haemorrhage in rabbits. Acta Neurochir (Wien). 2009;151:795–801.CrossRef
34.
Kästner S, Oertel MF, Scharbrodt W, Krause M, Böker DK, Deinsberger W. Endothelin-1 in plasma, cisternal CSF and microdialysate following aneurysmal SAH. Acta Neurochir (Wien). 2005;147:1271–9.CrossRef
35.
Ohkuma H, Parney I, Megyesi J, Ghahary A, Findlay JM. Antisense preproendothelin-oligoDNA therapy for vasospasm in a canine model of subarachnoid hemorrhage. J Neurosurg. 1999;90:1105–14.CrossRefPubMed
36.
Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery. 1998;43:863–75.CrossRefPubMed
37.
Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2000;92:390–400.CrossRefPubMed
38.
Xie A, Aihara Y, Bouryi VA, Nikitina E, Jahromi BS, Zhang ZD, et al. Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2007;27:1692–701.CrossRefPubMed
39.
Itoh S, Sasaki T, Asai A, Kuchino Y. Prevention of delayed vasospasm by an endothelin ETA receptor antagonist, BQ-123: change of ETA receptor mRNA expression in a canine subarachnoid hemorrhage model. J Neurosurg. 1994;81:759–64.CrossRefPubMed
40.
Sproviero D, Julien S, Burford B, Taylor-Papadimitriou J, Burchell JM. Cyclooxygenase-2 enzyme induces the expression of the α-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer. J Biol Chem. 2012;287:44490–7.CrossRefPubMedPubMedCentral
41.
Vivaldi A, Ciampi R, Tacito A, Molinaro E, Agate L, Bottici V, et al. Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. Mol Cell Endocrinol. 2012;355:41–8.CrossRefPubMed
42.
Mukherjee K, Gitlin JM, Loftin CD. Effectiveness of cyclooxygenase-2 inhibition in limiting abdominal aortic aneurysm progression in mice correlates with a differentiated smooth muscle cell phenotype. J Cardiovasc Pharmacol. 2012;60:520–9.CrossRefPubMed
43.
Ohkuma H, Tsurutani H, Suzuki S. Changes of beta-actin mRNA expression in canine vasospastic basilar artery after experimental subarachnoid hemorrhage. Neurosci Lett. 2001;311:9–12.CrossRefPubMed
44.
Shimamura N, Ohkuma H. Phenotypic transformation of smooth muscle in vasospasm after aneurysmal subarachnoid hemorrhage. Transl Stroke Res. 2014;5:357–64.CrossRefPubMed
45.
Hald ES, Alford PW. Smooth muscle phenotype switching in blast traumatic brain injury-induced cerebral vasospasm. Transl Stroke Res. 2014;5:385–93.CrossRefPubMed
46.
Edvinsson L, Larsen SS, Maddahi A, Nielsen J. Plasticity of cerebrovascular smooth muscle cells after subarachnoid hemorrhage. Transl Stroke Res. 2014;5:365–76.CrossRefPubMed
47.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071–80.CrossRefPubMed
48.
Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885–95.CrossRefPubMed
49.
ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1, e33.CrossRefPubMedCentral
Metadata
Title
Role of Cyclooxygenase-2 in Relation to Nitric Oxide and Endothelin-1 on Pathogenesis of Cerebral Vasospasm After Subarachnoid Hemorrhage in Rabbit
Authors
Akira Munakata
Masato Naraoka
Takeshi Katagai
Norihito Shimamura
Hiroki Ohkuma
Publication date
01-06-2016
Publisher
Springer US
Published in
Translational Stroke Research / Issue 3/2016
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-016-0466-6

Other articles of this Issue 3/2016

Translational Stroke Research 3/2016 Go to the issue

Original Article

Higher Insulin Resistance Level is Associated with Worse Clinical Response in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis

Original Article

Combination Protocol of Low-Frequency rTMS and Intensive Occupational Therapy for Post-stroke Upper Limb Hemiparesis: a 6-year Experience of More Than 1700 Japanese Patients

Original Article

Hydrogen Sulfide Attenuates Tissue Plasminogen Activator-Induced Cerebral Hemorrhage Following Experimental Stroke

Original Article

After Intracerebral Hemorrhage, Oligodendrocyte Precursors Proliferate and Differentiate Inside White-Matter Tracts in the Rat Striatum

Original Article

Troponin T in Prediction of Culprit Lesion Coronary Artery Disease and 1-Year Major Adverse Cerebral and Cardiovascular Events in Patients with Acute Stroke

Original Article

Effects of Early Post-Ischemic Reperfusion and tPA on Cerebrovascular Function and Nitrosative Stress in Female Rats